EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+7.85%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.92B
AUM Growth
+$2.92B
(-11%)
Cap. Flow
-$489M
Cap. Flow
% of AUM
-16.75%
Top 10 Holdings %
Top 10 Hldgs %
63.86%
Holding
67
New
12
Increased
7
Reduced
7
Closed
4
Top Buys
| 1 |
Jazz Pharmaceuticals
JAZZ
|
$77.2M |
| 2 |
Viridian Therapeutics
VRDN
|
$44.6M |
| 3 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$30.5M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$20M |
| 5 |
Relay Therapeutics
RLAY
|
$17.7M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$222M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$170M |
| 3 |
Galapagos
GLPG
|
$161M |
| 4 |
Aligos Therapeutics
ALGS
|
$53.1M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$39.8M |
Sector Composition
| 1 | Healthcare | 99.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $343M | 11.74% | 11,890,843 +283,418 | +2% | +$8.17M |
|
2
AnaptysBio
ANAB
$569M
| $261M | 8.94% | 7,794,996 +273,972 | +4% | +$9.18M |
|
3
Crinetics Pharmaceuticals
CRNX
$2.92B
| $219M | 7.5% | 4,288,120 +132,745 | +3% | +$6.78M |
|
4
Prothena Corp
PRTA
$441M
| $194M | 6.63% | 11,584,280 | – | – |
|
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $190M | 6.51% | 1,706,469 +692,517 | +68% | +$77.2M |
|
6
Zymeworks
ZYME
$1.12B
| $169M | 5.77% | 13,437,473 | – | – |
|
7
Arvinas
ARVN
$568M
| $166M | 5.67% | 6,726,491 | – | – |
|
8
Kura Oncology
KURA
$686M
| $113M | 3.88% | 5,806,871 | – | – |
|
9
Xencor
XNCR
$580M
| $107M | 3.67% | 5,330,416 | – | – |
|
10
Tango Therapeutics
TNGX
$747M
| $103M | 3.51% | 13,330,736 | – | – |
|
11
Janux Therapeutics
JANX
$1.37B
| $66.8M | 2.29% | 1,469,818 | – | – |
|
12
CRISPR Therapeutics
CRSP
$4.71B
| $65.3M | 2.23% | 1,389,276 | – | – |
|
13
Immunome
IMNM
$828M
| $56.7M | 1.94% | 3,879,415 | – | – |
|
14
Neurogene
NGNE
$264M
| $53.3M | 1.83% | 1,271,342 | – | – |
|
|
CNTA
15
Centessa Pharmaceuticals
CNTA
$2.25B
| $51.5M | 1.76% | 3,223,851 -2,490,553 | -44% | -$39.8M |
|
|
16
Viridian Therapeutics
VRDN
$1.5B
| $44.6M | 1.53% | +1,958,847 | New | +$44.6M |
|
17
Nuvation Bio
NUVB
$1.02B
| $44M | 1.51% | 19,209,643 | – | – |
|
|
THRD
18
DELISTED
Third Harmonic Bio
THRD
| $43.1M | 1.48% | 3,182,444 | – | – |
|
19
Vaxcyte
PCVX
$4B
| $40.3M | 1.38% | 352,464 +52,464 | +17% | +$6M |
|
20
Mersana Therapeutics
MRSN
$36.5M
| $36.6M | 1.25% | 19,364,688 | – | – |
|
21
Oric Pharmaceuticals
ORIC
$994M
| $35M | 1.2% | 3,418,068 | – | – |
|
22
Avidity Biosciences
RNA
$5.99B
| $34.8M | 1.19% | 757,576 | – | – |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $33.4M | 1.14% | 1,250,385 | – | – |
|
|
MBX
24
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $30.5M | 1.05% | +1,175,809 | New | +$30.5M |
|
25
Neumora Therapeutics
NMRA
$280M
| $27.4M | 0.94% | 2,071,450 | – | – |
|